Search

Now showing items 1-9 of 9

Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.

Blazing, MA; Cannon, CP; Charytan, DM; Lokhnygina, Y; Roe, Matthew Todd; Stanifer, John W; White, Jennifer (J Am Soc Nephrol, 2017-10)

Efficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems to diminish as eGFR declines. The strongest evidence supporting the cardiovascular benefit of statins in individuals with ...

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

AbouEzzeddine, OF; Anstrom, Kevin J; Bart, BA; DeVore, Adam David; Dunlay, SM; Felker, G Michael; Goldsmith, SR; ... (15 authors) (Circ Heart Fail, 2015-07)

BACKGROUND: Congestion is the most frequent cause for hospitalization in acute decompensated heart failure. Although decongestion is a major goal of acute therapy, it is unclear how the clinical components of congestion ...

Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Anstrom, Kevin J; Buggey, J; DeVore, Adam David; Eisenstein, EL; Ersbøll, MK; Fiuzat, M; Mentz, Robert John; ... (10 authors) (J Cardiovasc Pharmacol, 2015-05)

Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted ...

Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol.

Anstrom, Kevin J; Edwards, R; Eisenstein, EL; Enhanced Recovery Study Group; Gan, Tong Joo; Jin, Juying; Mantyh, Christopher Ritchie; ... (13 authors) (Anesth Analg, 2014-05)

BACKGROUND: Enhanced recovery after surgery (ERAS) is a multimodal approach to perioperative care that combines a range of interventions to enable early mobilization and feeding after surgery. We investigated the feasibility, ...

Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.

Jones, William; Patel, Manesh; Rockhold, Frank; Norgren, Lars; Hiatt, William R; Wojdyla, Daniel M; Fowkes, F Gerry R; ... (14 authors) (European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018-01)

OBJECTIVES:Critical limb ischaemia (CLI) implies an increased risk of cardiovascular morbidity and mortality, and the optimal antithrombotic treatment is not established. DESIGN, MATERIALS, METHODS:The EUCLID trial investigated ...

Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.

Rockhold, Frank; Lopes, Renato; Jones, William; Patel, Manesh; Berger, Jeffrey S; Abramson, Beth L; Heizer, Gretchen; ... (17 authors) (Vascular medicine (London, England), 2018-12)

Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD ...

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.

Jones, William; Lopes, Renato; Rockhold, Frank; Patel, Manesh; Low Wang, Cecilia C; Blomster, Juuso I; Heizer, Gretchen; ... (16 authors) (Journal of the American College of Cardiology, 2018-12)

BACKGROUND:Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic ...

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Hernandez, Adrian; Lopes, Renato; Mentz, Robert; Lokhnygina, Yuliya; Pagidipati, Neha; Jordan, Joseph; Bethel, M Angelyn; ... (21 authors) (Journal of the American Heart Association, 2018-10)

Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause ...